Rekah Pharmaceutical Industry Ltd - Asset Resilience Ratio
Rekah Pharmaceutical Industry Ltd (REKA) has an Asset Resilience Ratio of 0.01% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Rekah Pharmaceutical Industry Ltd total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2005–2025)
This chart shows how Rekah Pharmaceutical Industry Ltd's Asset Resilience Ratio has changed over time. See what is Rekah Pharmaceutical Industry Ltd's book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Rekah Pharmaceutical Industry Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see REKA stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 0% |
| Short-term Investments | ILA39.00K | 0.01% |
| Total Liquid Assets | ILA39.00K | 0.01% |
Asset Resilience Insights
- Limited Liquidity: Rekah Pharmaceutical Industry Ltd maintains only 0.01% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Rekah Pharmaceutical Industry Ltd Industry Peers by Asset Resilience Ratio
Compare Rekah Pharmaceutical Industry Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 35.10% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 4.31% |
|
Shandong Lukang Pharmaceutical Co Ltd
SHG:600789 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799 |
Drug Manufacturers - Specialty & Generic | 0.40% |
|
Shandong Shanda Wit Science and Technology Co Ltd
SHE:000915 |
Drug Manufacturers - Specialty & Generic | 25.22% |
Annual Asset Resilience Ratio for Rekah Pharmaceutical Industry Ltd (2005–2025)
The table below shows the annual Asset Resilience Ratio data for Rekah Pharmaceutical Industry Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.01% | ILA39.00K ≈ $104.56 |
ILA423.68 Million ≈ $1.14 Million |
+0.00pp |
| 2024-12-31 | 0.01% | ILA39.00K ≈ $104.56 |
ILA447.22 Million ≈ $1.20 Million |
+0.00pp |
| 2023-12-31 | 0.01% | ILA39.00K ≈ $104.56 |
ILA484.72 Million ≈ $1.30 Million |
-0.01pp |
| 2022-12-31 | 0.02% | ILA80.00K ≈ $214.48 |
ILA448.42 Million ≈ $1.20 Million |
+0.01pp |
| 2021-12-31 | 0.01% | ILA39.00K ≈ $104.56 |
ILA437.09 Million ≈ $1.17 Million |
0.00pp |
| 2020-12-31 | 0.01% | ILA40.00K ≈ $107.24 |
ILA419.69 Million ≈ $1.13 Million |
0.00pp |
| 2019-12-31 | 0.01% | ILA40.00K ≈ $107.24 |
ILA367.11 Million ≈ $984.21K |
0.00pp |
| 2018-12-31 | 0.01% | ILA43.00K ≈ $115.28 |
ILA300.28 Million ≈ $805.04K |
+0.00pp |
| 2017-12-31 | 0.01% | ILA29.00K ≈ $77.75 |
ILA294.95 Million ≈ $790.76K |
-0.54pp |
| 2016-12-31 | 0.55% | ILA1.78 Million ≈ $4.77K |
ILA322.72 Million ≈ $865.21K |
+0.01pp |
| 2015-12-31 | 0.54% | ILA1.75 Million ≈ $4.68K |
ILA323.82 Million ≈ $868.16K |
-0.85pp |
| 2014-12-31 | 1.39% | ILA4.30 Million ≈ $11.52K |
ILA310.11 Million ≈ $831.40K |
-0.34pp |
| 2013-12-31 | 1.72% | ILA5.22 Million ≈ $13.99K |
ILA303.16 Million ≈ $812.76K |
+0.59pp |
| 2012-12-31 | 1.14% | ILA3.38 Million ≈ $9.08K |
ILA298.07 Million ≈ $799.11K |
-2.08pp |
| 2011-12-31 | 3.21% | ILA9.22 Million ≈ $24.72K |
ILA286.99 Million ≈ $769.40K |
-3.30pp |
| 2010-12-31 | 6.52% | ILA18.76 Million ≈ $50.30K |
ILA287.97 Million ≈ $772.03K |
-2.23pp |
| 2009-12-31 | 8.74% | ILA24.34 Million ≈ $65.26K |
ILA278.40 Million ≈ $746.38K |
-0.45pp |
| 2008-12-31 | 9.19% | ILA26.70 Million ≈ $71.60K |
ILA290.50 Million ≈ $778.82K |
-2.66pp |
| 2007-12-31 | 11.85% | ILA35.68 Million ≈ $95.65K |
ILA300.96 Million ≈ $806.87K |
+0.91pp |
| 2006-12-31 | 10.94% | ILA32.45 Million ≈ $86.99K |
ILA296.53 Million ≈ $794.99K |
-2.98pp |
| 2005-12-31 | 13.92% | ILA37.18 Million ≈ $99.67K |
ILA267.00 Million ≈ $715.80K |
-- |
About Rekah Pharmaceutical Industry Ltd
Rekah Pharmaceutical Industry Ltd. engages in the manufacture, marketing, sale, and distribution of pharmaceuticals, cosmetics, vitamins and nutritional supplements, and medical devices in Israel. The company offers steroids, antibiotics, and ophthalmic products, as well as dermo-cosmetics products. Its portfolio of products comprise Rx and OTC drugs, and medical devices used in various therapeut… Read more